recent
global
outbreak
sever
acut
respiratori
syndrom
sar
quickli
gain
notorieti
newli
emerg
infecti
diseas
etiolog
agent
identifi
coronaviru
sarscov
close
relat
previous
character
coronavirus
septemb
total
probabl
case
sar
occur
death
antivir
treatment
current
avail
sarscov
sar
case
treat
symptomat
accord
sever
ill
treatment
protocol
consist
antibacteri
agent
combin
ribavirin
methylprednisolon
recent
propos
howev
therapeut
valu
ribavirin
remain
uncertain
activ
sarscov
vitro
molecular
model
studi
suggest
rhinoviru
pro
inhibitor
may
use
sar
therapi
result
recent
vitro
test
lead
molecul
neg
previou
studi
show
coronavirus
includ
avian
infecti
bronchiti
viru
murin
hepat
viru
human
coronaviru
suscept
type
interferon
vitro
vivo
therefor
evalu
vitro
efficaci
recombin
human
type
interferon
ifn
serono
intern
geneva
switzerland
three
differ
isol
sarscov
urbani
use
yield
reduct
assay
prepar
employ
studi
select
current
use
part
effect
treatment
regimen
relaps
form
multipl
sclerosi
importantli
shown
antivir
activ
measur
vesicular
stomat
viru
cytopath
assay
system
time
greater
current
avail
treatment
use
current
studi
vero
cell
treat
concentr
iuml
either
h
h
inocul
sarscov
multipl
infect
pfucel
monitor
cytopath
effect
product
infecti
sarscov
h
postinfect
inhibit
sarscov
depend
time
drug
administr
time
cultur
sampl
sarscov
infect
product
infecti
sarscov
potent
inhibit
log
pfuml
h
postinfect
pretreat
vero
cell
concentr
test
figur
h
postinfect
inhibit
sarscov
product
declin
three
sarscov
inhibit
detect
figur
urbani
isol
data
shown
somewhat
less
effect
inhibit
sarscov
replic
employ
infect
cultur
figur
nonetheless
product
infecti
sarscov
consider
reduc
log
pfuml
h
postinfect
protect
vero
monolay
sarscovinduc
cytopath
effect
preinfect
postinfect
treatment
dramat
even
h
postinfect
figur
addit
concentr
iuml
test
determin
inhibitori
concentr
ic
pretreat
vero
cell
concentr
low
iuml
posttreat
cell
concentr
iuml
provid
reduct
isol
h
postinfect
face
burgeon
epidem
sar
case
lack
effect
treatment
option
identifi
compound
antivir
activ
could
potenti
therapeut
becom
high
prioriti
report
suggest
may
effect
treatment
sarscov
infect
note
current
use
varieti
clinic
indic
includ
multipl
sclerosi
shown
dosedepend
efficaci
sever
clinic
trial
importantli
exhibit
potent
antivir
activ
dose
alreadi
shown
accept
safeti
profil
anim
thu
report
identif
compound
may
suitabl
rapid
develop
treatment
sarscov
infect
